Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni in Chronic HCV Patients With Autoimmune Disease
NCT02691728Phase 4Unknown
- Sponsor
- Peter J. Ruane, M.D.
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ledipasvir in hepatitis C (HCV), sponsored by Peter J. Ruane, M.D. Primary endpoints: Sustained Virologic Response 12 weeks after treatment completion at 24 weeks and Safety and Tolerability at 12 weeks. Status: unknown.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02691728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691728.